BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29790111)

  • 21. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
    Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
    J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 23. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer.
    Feng H; Cheng X; Kuang J; Chen L; Yuen S; Shi M; Liang J; Shen B; Jin Z; Yan J; Qiu W
    Cell Death Dis; 2018 Oct; 9(10):1030. PubMed ID: 30301881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: Pharmacokinetic and pharmacological study.
    Feng SL; Tian Y; Huo S; Qu B; Liu RM; Xu P; Li YZ; Xie Y
    Phytomedicine; 2020 Feb; 67():153141. PubMed ID: 31884406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
    Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
    Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent antitumor activity of novel taxoids in anaplastic thyroid cancer.
    Wang M; Wang C; Feng C; Guo W; Chen H; Liu B; Li E; Liu W; Taouil A; Ojima I; Hou P
    Endocrine; 2022 Feb; 75(2):465-477. PubMed ID: 34591230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.
    Gao H; Wang W; Li Q
    Cancer Biol Ther; 2022 Dec; 23(1):369-377. PubMed ID: 35491899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells.
    Gao L; Liu G; Ma J; Wang X; Wang F; Wang H; Sun J
    Colloids Surf B Biointerfaces; 2014 May; 117():122-7. PubMed ID: 24632038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.
    Kocdor MA; Cengiz H; Ates H; Kocdor H
    Anticancer Agents Med Chem; 2019; 19(15):1887-1898. PubMed ID: 31584382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.
    Wong Te Fong AC; Thavasu P; Gagrica S; Swales KE; Leach MO; Cosulich SC; Chung YL; Banerji U
    Oncotarget; 2017 Dec; 8(69):113874-113884. PubMed ID: 29371953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.
    Pinto N; Prokopec SD; Ghasemi F; Meens J; Ruicci KM; Khan IM; Mundi N; Patel K; Han MW; Yoo J; Fung K; MacNeil D; Mymryk JS; Datti A; Barrett JW; Boutros PC; Ailles L; Nichols AC
    PLoS One; 2020; 15(9):e0239315. PubMed ID: 32970704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.
    Garg M; Kanojia D; Okamoto R; Jain S; Madan V; Chien W; Sampath A; Ding LW; Xuan M; Said JW; Doan NB; Liu LZ; Yang H; Gery S; Braunstein GD; Koeffler HP
    J Clin Endocrinol Metab; 2014 Jan; 99(1):E62-72. PubMed ID: 24170107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism.
    Ma L; Fei H
    J Bioenerg Biomembr; 2020 Apr; 52(2):123-130. PubMed ID: 32036542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.
    Pilli T; Cantara S; Marzocchi C; Pacini F; Prabhakar BS; Castagna MG
    Endocrine; 2020 Jan; 67(1):117-123. PubMed ID: 31377969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
    Pan Y; Liu P; Chen D; Dou L
    Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice].
    Liao H; Wang Y; Xu X; Zhou C; Zhang J; Zhong K; Yang D
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jul; 41(7):1056-1061. PubMed ID: 34308856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.
    Karthikeyan S; Hoti SL; Nazeer Y; Hegde HV
    Oncotarget; 2016 Jul; 7(27):42353-42373. PubMed ID: 27304668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K; Yu M; Hao F; Dong A; Chen D
    Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; Fallahi P; La Motta C; Ferrari SM; Mancusi C; Fioravanti A; Di Desidero T; Sartini S; Corti A; Piaggi S; Materazzi G; Spinelli C; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.